Global Intravenous (IV) Iron Drugs Market

Potential Opportunities

Publication Date	February 2009
Publisher	Koncept Analytics
Product Type	Report
Pages	32
ISBN Number	not applicable
Product Code	KOA04342

Buy this product or for assistance call +44 20 7060 7474

PDF £480.00$798 | €537

FAX Order above formats by FAX

Summary

Iron deficiency anemia or IDA is among one of the top ten most important public health issues, according to the World Health Organization. With approximately one-third of the current global population facing the problem of iron deficiency, more and more people are likely to suffer from a lack of iron in their diet in the near future due to changes in eating habits and rising life expectancy.

Currently, iron supplements used in the context of IDA account for the majority share of the iron-based medicines but this is likely to change with the growing utility of intravenous iron (IV) drugs. Earlier, the IV iron market was mainly achieved in the hemodialysis (HD) setting, but IV iron is likely to be used more in many other therapeutic areas which are highly under-penetrated.

One of the major attractiveness of IV iron especially in regions outside the United States is its pricing and growing number of CKD population. Generally the pricing of IV irons outside the U.S. is lower and the iron market in countries like China is underdeveloped, but growing rapidly, with tremendous potential.

Venofer from Galenica Limited has emerged as the undisputed leader in the IV iron drugs market overtaking the market share of Watson's InFed and Ferrlecit. Still the whole IV iron market holds immense business opportunities mainly because of increase in the number of haemodialysis patients and limitation in various iron replacement therapies and scope for innovation.

The report titled ""Global Intravenous (IV) Iron Drugs Market: Potential Opportunities"" analyzes the IV iron market in the context of opportunities it holds for iron drug manufacturers. The report presents statistics on the growing population of patients who are suffering from critical conditions that calls for the need of iron drugs. Further, it analyzes the factors that could drive the growth of IV drugs market in the future. It also profiles the two major manufacturers of iron drugs - Galenica and Watson Pharma. Further, the future growth of the IV iron drugs market has been analyzed in the report.

Content

1. Iron Deficiency Anemia: An Overview
- 1.1 Introduction - Iron Deficiency Anemia
- 1.2 Prevalence of iron deficiency anemia
2. Chronic Kidney Disease (CKD) and IV Iron Products
- 2.1 Prevalence of CKD
- 2.2 CKD associated anemia
- 2.3 Prevalence of CKD associated anemia
- 2.4 CKD associated anemia - Therapies
  - 2.4.1 Oral Iron Repletion Therapy
  - 2.4.2 Intravenous Iron Infusion Therapy
- 2.5 Applications of IV iron products in therapeutic areas
3. Global Market for Iron-Based Medicines
4. Intravenous Iron (IV) Drugs: Global Market
5. US Intravenous Iron (IV) Drugs Market
6. Growth Drivers
7. Market Opportunities
8. Competitive Landscape
9. Leading IV Drugs Companies
- 9.1 Galenica Ltd. (Venofer and Ferinject)
  - 9.1.1 Company Description
  - 9.1.2 Major Products
  - 9.1.3 Business Strategies
- 9.2 Watson Pharma (Ferrlecit and InFed)
  - 9.2.1 Company Description
  - 9.2.2 Major Products
  - 9.2.3 Business Strategies
10. Market Forecast
Tables and Figures
- Table 1.1: Stages of chronic kidney disease
- Figure 2.1: Prevalence of CKD in the US Population: 1996-2020
- Figure 2.1: US CKD: Patients undergoing Dialysis & receiving Iron Treatment
- Figure 3.1: Global Market of Iron Products: 2003-2007
- Figure 3.2: Market Share of Oral and IV Iron Drugs: 2007
- Figure 4.1: Global IV Iron Market: 2006 & 2007 (Forecast 2008-2010)
- Figure 4.2: Global IV Iron Sales Break-up (In & outside dialysis CKD): 2006 & 2007 (Forecast 2008-2010)
- Figure 4.3: Global IV Iron Sales by Geography: 2007
- Figure 5.1: US CKD Patient Profile
- Figure 5.2: US IV Iron Market: 2006 & 2007 (Forecast 2008-2010)
- Figure 5.3: US Intravenous Iron Market - Share by Brands: 2007
- Figure 6.1: Number of dialysis patients worldwide - Trends (2004-2015)
- Figure 6.2: Prevalence of Diabetes in Five Major Countries: 2000 & 2010
- Figure 6.3: Incidence of ESRD by year (per million population): Major Countries
- Figure 6.4: Prevalence of ESRD by year (per million population): Major Countries
- Figure 7.1: IV Market Potential - Major therapeutic areas
- Figure 8.1: Global Iron Drugs Supplement Market Share: 2006
- Figure 8.2: Global Market Share of leading IV iron drugs players: 2003-07
- Figure 8.3: Global Market Share of Parenteral IV Drugs: 2007
- Figure 10.1: Global IV Iron Market Forecast: 2008-2010
- Figure 10.2: CKD Dialysis & Non Dialysis: Patients receiving Iron Treatment